Rigel Pharmaceuticals Inc
F:RI2A
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
Rigel Pharmaceuticals Inc
F:RI2A
|
US |
|
A
|
Angi Inc
F:2UH
|
US |
|
A
|
Autozone Inc
XBER:AZ5
|
US |
|
A
|
Accuray Inc
SWB:XEJ
|
US |
|
T
|
thyssenkrupp AG
DUS:TKA
|
DE |
|
US Gold Corp
NASDAQ:USAU
|
US |
|
Buckle Inc
NYSE:BKE
|
US |
|
R
|
ReproCell Inc
F:6RC
|
JP |
|
Bank Syariah Indonesia Tbk PT
IDX:BRIS
|
ID |
|
Ajinomoto Co Inc
TSE:2802
|
JP |
|
P
|
PetroChina Co Ltd
XBER:PC6
|
CN |
|
N
|
Nov Inc
XBER:NO8
|
US |
Wall St Price Targets
RI2A Price Targets Summary
Rigel Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for RI2A is 19.08 EUR with a low forecast of 13.49 EUR and a high forecast of 29.9 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is RI2A's stock price target?
Price Target
19.08
EUR
According to Wall Street analysts, the average 1-year price target for RI2A is 19.08 EUR with a low forecast of 13.49 EUR and a high forecast of 29.9 EUR.
What is the Revenue forecast for Rigel Pharmaceuticals Inc?
Projected CAGR
-2%
Over the last 13 years, the compound annual growth rate for Revenue has been 45%. The projected CAGR for the next 8 years is -2%.
What is the Operating Income forecast for Rigel Pharmaceuticals Inc?
Projected CAGR
-7%
The compound annual growth rate for Operating Income over the next 8 years is -7%.
What is the Net Income forecast for Rigel Pharmaceuticals Inc?
Projected CAGR
-17%
The compound annual growth rate for Net Income over the next 8 years is -17%.
